ProciseDx Revenue and Competitors
Estimated Revenue & Valuation
- ProciseDx's estimated annual revenue is currently $3.8M per year.
- ProciseDx's estimated revenue per employee is $135,000
- ProciseDx's total funding is $13M.
Employee Data
- ProciseDx has 28 Employees.
- ProciseDx grew their employee count by -24% last year.
ProciseDx's People
Name | Title | Email/Phone |
---|---|---|
1 | Sr. VP | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | CEO & CSO | Reveal Email/Phone |
4 | VP, QUALITY & REGULATORY | Reveal Email/Phone |
5 | VP, International | Reveal Email/Phone |
6 | Associate Director, Instrumentation | Reveal Email/Phone |
7 | Sr. Director Clinical Development and Regulatory Affairs | Reveal Email/Phone |
8 | Senior Director, R&D | Reveal Email/Phone |
9 | Associate Director Clinical Operations | Reveal Email/Phone |
10 | DIRECTOR, AUTOMATION & INSTRUMENTATION | Reveal Email/Phone |
ProciseDx Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.3M | 156 | -3% | N/A | N/A |
#2 | $148.5M | 440 | N/A | N/A | N/A |
#3 | $124.2M | 368 | 46% | N/A | N/A |
#4 | $545.1M | 1442 | 17% | N/A | N/A |
#5 | $29.2M | 108 | 6% | N/A | N/A |
#6 | $12.9M | 53 | N/A | N/A | N/A |
#7 | $1125.1M | 2914 | 6% | $20.4M | N/A |
#8 | $15.3M | 63 | 15% | N/A | N/A |
#9 | $8.9M | 41 | 5% | N/A | N/A |
#10 | $4.3M | 23 | -15% | N/A | N/A |
What Is ProciseDx?
ProciseDx is helping patients leave appointments with answers instead of just another appointment. Our point-of-care diagnostic solutions are enabling faster decisions for patients and physicians.
keywords:N/A$13M
Total Funding
28
Number of Employees
$3.8M
Revenue (est)
-24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.2M | 28 | 33% | $18M |
#2 | $4.1M | 28 | N/A | N/A |
#3 | $2M | 28 | 4% | $8.9M |
#4 | $3.5M | 28 | 47% | $30.1M |
#5 | $3.6M | 28 | -3% | N/A |